|
BACKGROUND
Chronic denervation is one of the harmful consequences of long regeneration times and distance that profoundly inhibits functional recovery following nerve injuries. Surgical strategies that demonstrate the ability to protect against chronic denervation may do so by supplementing the growth supportive, neurotrophic environment within the denervated nerve stump. The Schwann cell response to injury is a critical event following peripheral nerve injury because it contributes to generating an environment conducive to axonal regeneration. A family of growth factors known as “neuregulins” are closely associated with a surge in Schwann cell proliferation.
Neuregulin is a ligand for the ErbB2 family. Inhibition of ErbB2 has been shown to accelerate early axon regeneration and stimulate Schwann cell proliferation within a denervated nerve stump, independent of neuregulin signaling.
DESCRIPTION OF THE INVENTION
Our researchers at SickKids have demonstrated the use of an inhibitor of the ErbB2 receptor for treatment or repair of nerves/nerve tissues. A dosing protocol for treatment for peripheral nerve regeneration after injuries has been tested in a rodent model. This protocol involves an intravenous administration after injury and can be used for neuropathies or for pre-surgical and/or post-surgical intervention.
COMMERCIAL APPLICATIONS & ADVANTAGES
- Novel approach to improving nerve regeneration following peripheral nerve damage.
- Neuropathies, such as diabetic neuropathy, or chemotherapy-induced neuropathy
- Drug is currently in clinical use for other indications
DEVELOPMENT STAGE
Pre-clinical evaluations
PATENT STATUS
- Full US Patent number 11,053,321
- Full European Patent has been filed
- Full Canadian Patent has been filed
|
|
